La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Hims & Hers Health Gestion
Gestion contrôle des critères 2/4
Hims & Hers Health's CEO is Andrew Dudum, appointed in Jan 2017, has a tenure of 7.58 years. total yearly compensation is $14.40M, comprised of 4.2% salary and 95.8% bonuses, including company stock and options. directly owns 8.85% of the company’s shares, worth $318.27M. The average tenure of the management team and the board of directors is 2.4 years and 2.7 years respectively.
Informations clés
Andrew Dudum
Directeur général
US$14.4m
Rémunération totale
| Pourcentage du salaire du PDG | 4.2% |
| Durée du mandat du directeur général | 7.6yrs |
| Propriété du PDG | 8.9% |
| Durée moyenne d'occupation des postes de direction | 2.4yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 2.7yrs |
Mises à jour récentes de la gestion
Recent updates
Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade
Aug 20Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump
Aug 11
Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage
Aug 07Hims & Hers: The Thesis Goes Far Beyond GLP-1
Jul 18Hims & Hers: Buy The Dip To Catch The Next Rip
Jun 24Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge
Jun 19Hims & Hers: The Undervalued Gem Poised For Growth
Jun 18Beyond The Marketing Machine: Why Hims & Hers Stock Might Be Vulnerable
Jun 10Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment
May 31Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead
May 21Hims & Hers Health: An Unforced Error
May 06Hims & Hers Health, Inc. (NYSE:HIMS) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
May 04Hims & Hers Health: Becoming A Market Leader Within The Growing Digital Health Industry
Apr 24Hims & Hers Health: Strong Prospects But Weak Business Model Consolidation
Apr 05Hims & Hers: 5 Reasons Why This Is A Phenomenal Long-Term Growth Stock
Mar 21Pills Pay The Bills: Mini Deep Dive On Hims & Hers Health
Mar 12Investors Appear Satisfied With Hims & Hers Health, Inc.'s (NYSE:HIMS) Prospects As Shares Rocket 49%
Feb 28Hims & Hers: Turning The Profitability Corner And Returning 28%
Feb 25Hims & Hers Health: No Clear Moat Besides First Mover Advantage
Jan 23Hims & Hers Health: Unleashing Macro Momentum - Investing In Growth At A Higher Multiple
Jan 10Investors Still Waiting For A Pull Back In Hims & Hers Health, Inc. (NYSE:HIMS)
Jan 07Hims & Hers Health Q3: The Cheapest Growth Stock Around
Dec 14Hims & Hers Health: What Would The Author Of 100 Baggers Say?
Nov 30Hims & Hers: The Most Undervalued Small Cap Stock I See
Nov 08Hims & Hers: A Promising Company With Resolvable Challenges
Nov 02Hims & Hers: Specialization Is The Secret To Great Growth
Oct 25Hims & Hers Health: Can't Get Much Better
Sep 25The Market Is Wrong On Hims & Hers Health
Sep 18Hims & Hers: The Current Weakness Creates A Buying Opportunity
Aug 15Hims & Hers Health: Giving Investors Another Bite At The Apple
Aug 01Hims & Hers Health, Inc.'s (NYSE:HIMS) Price In Tune With Revenues
Jul 21Hims & Hers Health: Expect Strong EBITDA Growth As Revenue Growth Remains Strong
Jul 13Hims & Hers Health: Double-Edged Sword
Jul 02Hims & Hers: More Transparency Could Help The Stock
Jun 09Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$18m |
| Mar 31 2024 | n/a | n/a | -US$2m |
| Dec 31 2023 | US$14m | US$612k | -US$24m |
| Sep 30 2023 | n/a | n/a | -US$36m |
| Jun 30 2023 | n/a | n/a | -US$47m |
| Mar 31 2023 | n/a | n/a | -US$59m |
| Dec 31 2022 | US$11m | US$600k | -US$66m |
| Sep 30 2022 | n/a | n/a | -US$86m |
| Jun 30 2022 | n/a | n/a | -US$83m |
| Mar 31 2022 | n/a | n/a | -US$73m |
| Dec 31 2021 | US$15m | US$574k | -US$108m |
| Sep 30 2021 | n/a | n/a | -US$82m |
| Jun 30 2021 | n/a | n/a | -US$72m |
| Mar 31 2021 | n/a | n/a | -US$63m |
| Dec 31 2020 | US$27m | US$527k | -US$18m |
| Sep 30 2020 | n/a | n/a | -US$25m |
| Jun 30 2020 | n/a | n/a | -US$38m |
| Mar 31 2020 | n/a | n/a | -US$58m |
| Dec 31 2019 | US$254k | US$254k | -US$72m |
Rémunération vs marché: Andrew's total compensation ($USD14.40M) is above average for companies of similar size in the US market ($USD6.76M).
Rémunération et revenus: Andrew's compensation has been consistent with company performance over the past year.
PDG
Andrew Dudum (35 yo)
7.6yrs
Titularisation
US$14,401,411
Compensation
Mr. Andrew Dudum serves as Chairman of the Board and serves as Chief Executive Officer at Hims & Hers Health, Inc. since January 20, 2021. He Co-Founded Hims & Hers Health, Inc. in 2017. He is Co-founded H...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Co-Founder | 7.6yrs | US$14.40m | 8.85% $ 318.3m | |
| Chief Financial Officer | 2.6yrs | US$7.43m | 0.085% $ 3.0m | |
| Chief Operating Officer | 3.6yrs | US$6.77m | 0.27% $ 9.7m | |
| Chief Legal Officer & Corporate Secretary | 3.6yrs | US$5.21m | 0.076% $ 2.7m | |
| Chief Medical Officer | 1.7yrs | US$198.26k | 0.093% $ 3.4m | |
| Chief Commercial Officer | less than a year | US$6.71m | 0.085% $ 3.1m | |
| Senior VP | 5.2yrs | US$961.12k | 0.0013% $ 48.2k | |
| Chief Communications Officer | less than a year | pas de données | pas de données | |
| Senior Vice President of Human Resources | 2.4yrs | pas de données | pas de données | |
| Senior VP & Member of Medical Advisory Board | no data | pas de données | pas de données | |
| Chief Pharmacy & Innovation Officer | 1.7yrs | pas de données | pas de données | |
| Senior Vice President of Mental Health | 1.4yrs | pas de données | pas de données |
2.4yrs
Durée moyenne de l'emploi
44yo
Âge moyen
Gestion expérimentée: HIMS's management team is considered experienced (2.4 years average tenure).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Co-Founder | 3.6yrs | US$14.40m | 8.85% $ 318.3m | |
| Chief Medical Officer | 2.5yrs | US$198.26k | 0.093% $ 3.4m | |
| Senior VP & Member of Medical Advisory Board | 2.6yrs | pas de données | pas de données | |
| Independent Director | 3.9yrs | US$194.26k | 0.025% $ 900.9k | |
| Lead Independent Director | 3.9yrs | US$227.41k | 0.086% $ 3.1m | |
| Independent Director | 3.4yrs | US$205.51k | 0.034% $ 1.2m | |
| Member of Medical Advisory Board | 2.7yrs | pas de données | pas de données | |
| Member of Medical Advisory Board | no data | pas de données | pas de données | |
| Member of Medical Advisory Board | 2.7yrs | pas de données | pas de données | |
| Member of Medical Advisory Board | 2.7yrs | pas de données | pas de données | |
| Member of Medical Advisory Board | 2.7yrs | pas de données | pas de données | |
| Member of Medical Advisory Board | 2.7yrs | pas de données | pas de données |
2.7yrs
Durée moyenne de l'emploi
53yo
Âge moyen
Conseil d'administration expérimenté: HIMS's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.